http://orcid.org/0000-0002-6055-8968
References
- Tintore M, Vidal-Jordana A, Sastre-Garriga J. Treatment of multiple sclerosis – success from bench to bedside. Nat Rev Neurol. 2019;15:53–58.
- Winkelmann A, Loebermann M, Reisinger EC, et al. Disease modifying therapies and infectious risks in multiple sclerosis. Nat Rev Neurol. 2016;12:217–233.
- Manouchehri N, Mirmosayyeb O, Badihian S, et al. Cutaneous anaplastic large cell lymphoma in a multiple sclerosis patient receiving Fingolimod. Mult Scler Relat Disord. 2018;19:121–123.
- Connolly A, Grandi V, Stefanato CM, et al. Primary cutaneous CD30+ anaplastic large-cell lymphoma associated with fingolimod. Br J Dermatol. 2018;179:1400–1401.
- Cesbron E, Monfort JB, Giannesini C, et al. Primary cutaneous CD30+ T-cell lymphoproliferation during treatment with fingolimod: case report and literature review. Ann Dermatol Venereol. 2018;145:433–438.
- Papathemeli D, Gräfe R, Hildebrandt U, et al. Development of a primary cutaneous CD30(+) anaplastic large-cell T-cell lymphoma during treatment of multiple sclerosis with fingolimod. Mult Scler. 2016;22:1888–1890.
- Nitsan Z, Kucuk N, Appel S, et al. Mycosis fungoides - a cutaneous lymphoproliferative disorder in a patient treated with fingolimod for multiple sclerosis. J Clin Neurosci. 2018;48:102–103.
- Froehlich A, Schmidt S, Landsberg J, et al. Spontaneous regression of tumor-stage cutaneous T-cell lymphoma in a multiple sclerosis patient after discontinuing fingolimod. Mult Scler. 2018;24:1785–1787.
- Samaraweera AP, Cohen SN, Akay EM, et al. Lymphomatoid papulosis: a cutaneous lymphoproliferative disorder in a patient on fingolimod for multiple sclerosis. Mult Scler. 2016;22:122–124.
- Matoula T, Nikolaou V, Marinos L, et al. Lymphomatoid papulosis type D in a fingolimod-treated multiple sclerosis patient. Mult Scler. 2016;22:1630–1631.
- Stitt DW, Boes CJ, Flanagan EP, et al. A case of cutaneous large B-cell lymphoma during treatment of multiple sclerosis with fingolimod. Mult Scler Relat Disord. 2018;19:115–117. Nat Rev Neurol. 2016;12(4):217–233.
- Kira J, Itoyama Y, Kikuchi S, et al. Fingolimod (FTY720) therapy in Japanese patients with relapsing multiple sclerosis over 12 months: results of a phase 2 observational extension. BMC Neurol. 2014;14:21.
- Christopher KL, Elner VM, Demirci H. Conjunctival lymphoma in a patient on fingolimod for relapsing-remitting multiple sclerosis. Ophthalmic Plast Reconstr Surg. 2017;33:e73–e75.
- Gaulard P, Swerdlow SH, Harris NL, et al., editors. Other iatrogenic immunodeficiency-associated lymphoproliferative disorders. In: Swerdlow SH, Campo E, Harris NL, et al. WHO classification of tumors of hematopoietic and lymphoid tissues revised. 4th ed. Lyon: IRAC; 2017. p. 462–464.
- Pyne NJ, McNaughton M, Boomkamp S, et al. Role of sphingosine 1-phosphate receptors, sphingosine kinases and sphingosine in cancer and inflammation. Adv Biol Regul. 2016;60:151–159.